Defective neuritogenesis in Abcd1/2 deficient rat neurons due to intrinsic and astrocyte-dependent mechanisms
Arantxa GolbanoiD, Luis PardoiD, Carmen MenachoiD, Marina RierolaiD, Enrique ClaroiD, Levi Benjamin WoodiD, Roser MasgrauiD, Elena GaleaiD
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a rare neurometabolic and demyelinating disorder caused by loss of function mutations of the ABCD1 transporter that imports very-long-chain fatty acids (VLCFA) into the peroxisome for beta-oxidation. Impaired ABCD1 function results in VLCFA accumulation, which ultimately causes lethal forms of X-ALD in children (CCALD) and adults (CAMN). Because X-ALD is a genetic disorder, we looked for signs of altered neurodevelopmental pathways in the transcriptomes of brain cortical tissues free of pathology from patients that died of CALD or CAMN. Several categories related to brain development, axonal growth, synaptic signaling and synaptic compartments were significantly dysregulated in both CALD and CAMN, suggesting that congenital circuit abnormalities might be structural in brains of mutated ABCD1 carriers. We partially dissected the cellular origin of dysregulated pathways using rat neuronal and astrocytic cultures in which X-ALD was modeled by silencing of Abcd1 and Abcd2 by RNA interference. Abcd2 was silenced lest it compensated for Abcd1 loss. Abcd1/2 deficient neurons presented higher rates of death, reduced sizes and defective formation of spines, dendrites and axons. The aberrant neuron development was caused by cell-autonomous and astrocyte-dependent mechanisms, and involved Wnt signaling, as suggested by the rescue of the expression of a synaptic gene upon pharmacological activation of the Wnt pathway. As recently proposed for neurogenetic disorders such as Huntingtons disease, our data suggest that X-ALD has a neurodevelopmental component that may cause psychiatric alterations and prime neural circuits for neurodegeneration. If this is the case, therapies aimed at restoring neural-circuit function in neurodevelopmental disorders may be reprofiled for X-ALD therapeutics.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- iPSC-derived astrocytes to model phenotype-specific differential neuroinflammatory and metabolic responses in X-linked adrenoleukodystrophy
Parveen Parasar, Navtej Kaur, … Jaspreet Singh·bioRxiv·Sep 9, 2022
- Genetic analysis of the X-linked Adrenoleukodystrophy ABCD1 gene in Drosophila uncovers a role in Peroxisomal dynamics
Joshua Manor, Sharayu V. Jangam, … Michael F. Wangler·bioRxiv·Sep 23, 2024
- Generating human AMN and cALD iPSC-derived astrocytes with potential for modeling X-linked adrenoleukodystrophy phenotypes
Navtej Kaur, Jaspreet Singh·bioRxiv·May 31, 2024
- A novel mouse model of cerebral adrenoleukodystrophy highlights NLRP3 activity in lesion pathogenesis
Ezzat Hashemi, Isha N. Srivastava, … Keith P. van Haren·Annals of NeurologyPeer-reviewed·Oct 28, 2024
- Pharmacological complementation remedies an inborn error of lipid metabolism
M. D. Hartley, M. D. Shokat, … T. S. Scanlan·bioRxiv·Jan 31, 2020
- Multi-omic approach to identify phenotypic modifiers underlying cerebral demyelination in X-linked adrenoleukodystrophy
Phillip A. Richmond, Frans M. van der Kloet, … Clara van Karnebeek·Frontiers in Cell and Developmental BiologyPeer-reviewed·Jun 25, 2020